Family Medicine Doctors in Mount Shasta, CA Accepting Medicare

8 Family Medicine doctors found. Showing 1 - 8

Dr. Erik James Van Houten, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 101 Old Mccloud Rd, Mount Shasta, CA 96067 Phone: 530-999-9040

David Glenn Holst, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 824 Pine St, Mount Shasta, CA 96067 Phone: 530-926-4528    Fax: 530-926-5070

Dr. John Milo Katana, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 408 Pine St, Mount Shasta, CA 96067 Phone: 530-926-7196    Fax: 530-926-1026

Dr. Phillip M Miller, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 408 Pine St, Mount Shasta, CA 96067 Phone: 530-926-7196    Fax: 530-926-1026

Dr. John Karl Capos, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 620 S Mount Shasta Blvd, Mount Shasta, CA 96067 Phone: 530-918-6037    Fax: 530-918-6039

Dr. Ashley Denise Delaney, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 101 Old Mccloud Rd, Mount Shasta, CA 96067 Phone: 530-999-9040

Danny Elliott Drew, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 110 W Castle St, Ste 100, Mount Shasta, CA 96067 Phone: 530-926-9897    Fax: 530-926-2217

Ronald Kaminski Lagro, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 912 Pine St, Mount Shasta, CA 96067 Phone: 530-926-7131    Fax: 530-926-7134

News Archive

Study finds increased opioid consumption two years after intensive care

Nearly 11 percent of people admitted to an intensive care unit in Sweden between 2010 and 2018 received opioid prescriptions on a regular basis for at least six months and up to two years after discharge.

FDA approves Warner Chilcott's ACTONEL for postmenopausal osteoporosis

Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL® (risedronate sodium) product for the treatment of postmenopausal osteoporosis in the United States. The product will be marketed as ATELVIA™ (risedronate sodium) delayed-release tablets.

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

Majority of Canadians confuse sinusitis with H1N1 symptoms

It's winter, that great Canadian season of snow, ice, grey skies...and colds and the flu. In a year when H1N1 is high on everyone's radar, it is more important than ever for Canadians to know what their symptoms mean and when they should see their doctor.

Physical activity reduces CVD mortality risk in patients with hypertension

In the study, all-cause and CVD mortality risks were found to be significantly higher among study participants that didn't exercise compared with active participants at all blood pressure levels. Moreover, the excess mortality risks of physical inactivity, when converted into a "blood pressure equivalence of physical activity" measurement, revealed that physical inactivity was similar to a rise in mortality risk equivalent to an increase in blood pressure of 40-50 mmHg.

Read more Medical News

› Verified 9 days ago